Business Wire

Cogeco Peer 1 Changes Name to Aptum Technologies; Adds New Services to Enhance and Expand Hybrid Cloud Offerings

Share

Cogeco Peer 1, a managed hosting and cloud services provider, today announced it has changed its name to Aptum Technologies. The move follows the April 2019, acquisition of Cogeco Peer 1 by Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190819005121/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Susan Bowen, CEO of Aptum (Photo: Business Wire)

“Aptum means ‘adaptability’ and reflects our heritage and vision for the future,” said Susan Bowen, Chief Executive Officer of Aptum. “As businesses face exponentially increasing volumes of information, and data becomes an integral part of their infrastructure, technology platforms must adapt and harness the power of data to enable better decision making, risk evaluation and customer engagement. We help organizations unlock the potential of their data by providing a robust infrastructure that enables customers to solve complex challenges and maximize the potential of their businesses.”

Headquartered in Toronto, Aptum will operate with two focused business units — Data Center and Fiber. The Data Center business will concentrate on enabling multi-cloud services for enterprises. The Fiber business will be Canada’s first independent, neutral-host provider of small cell and 5G infrastructure, and enterprise and wholesale fiber connectivity with an extensive metro fiber network across greater Toronto and Montreal.

With a 20-year heritage helping customers maximize technologies to store, manage, move and secure their critical data, Aptum is one of a select group of companies able to offer true hybrid infrastructure solutions with secure data center, cloud, connectivity and managed services across North and Central America, Europe, the Middle East and Africa.

Aptum is led by an experienced executive team that includes:

  • Susan Bowen, Chief Executive Officer
  • Shenif Visram, Chief Finance Officer
  • Sanjay Sachdev, President and Head of Fiber
  • Leighton Plumley, Chief Revenue Officer (Data Center Business Unit)
  • Cindy Jordan-Ford, EVP Global Strategic Accounts & Alliances
  • Jeremy Pease, Chief Operating Officer
  • Scott Davis, Interim Chief Infrastructure Officer
  • Paul Dyck, Vice President, Human Resources

Concurrent with the rebranding, Aptum has launched two new offerings that expand and enhance its customers’ hybrid cloud options:

  • Managed Amazon Web Services (AWS) – reinforcing Aptum’s commitment to multi-cloud this new suite of AWS services complements Aptum’s existing Managed Azure and Managed Private Cloud offerings. Managed AWS services include consultation; architecture/design; solution build and configuration; migration; project management; ongoing service management and optimization; and 24/7 expert support. Managed AWS is available in Canada, the U.S. and the U.K.
  • New Cloud Connect Availability – expansion of Cloud Connect, which offers a direct, dedicated and secure connection to cloud services. Cloud Connect is now available for AWS Direct Connect, Google Cloud Platform, ServiceNow, Salesforce, SAP and Oracle in addition to Microsoft ExpressRoute. The Cloud Connect expansion is available in all regions.

“The addition of these new cloud services is a perfect example of how Aptum is continually evolving to meet our customers’ changing needs,” Bowen said. “Every business has unique considerations, constraints and objectives that will be met by different solutions. Helping customers determine the correct platform for their unique requirements and then providing expert implementation is why businesses turn to Aptum.”

“As a rapidly growing AI products company, Element AI needed a true partner that could help us focus on our business growth rather than worrying about our data center infrastructure. For the past two years, Cogeco Peer 1 has consistently delivered,” said Ludwig Gamache, IT Director, Element AI. “Our requirements are different from most companies because of the compute-intensive nature of machine learning and AI algorithms – which generate more heat to dissipate and higher power demands than average customers. Element AI is now 35 times bigger than when we launched in 2016, and Cogeco Peer 1 has been able to adapt to solve our unique challenges. We look forward to continuing to evolve our IT infrastructure with Aptum as we grow."

Resources:

About Aptum Technologies

Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Connectivity solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America and Europe. In Canada, through its Fiber business, Aptum is the first neutral host provider of turnkey small cell connectivity, augmenting an extensive metro network across Toronto and Montreal. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cindy Watson/Mike Martin
StrategicAmpersand
AptumPR@stratamp.com
416-961-5595

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye